GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CBD Life Sciences Inc (OTCPK:CBDL) » Definitions » LT-Debt-to-Total-Asset

CBD Life Sciences (CBD Life Sciences) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2015)


View and export this data going back to 2009. Start your Free Trial

What is CBD Life Sciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CBD Life Sciences's long-term debt to total assests ratio for the quarter that ended in Sep. 2015 was 0.00.

CBD Life Sciences's long-term debt to total assets ratio stayed the same from Sep. 2014 (0.00) to Sep. 2015 (0.00).


CBD Life Sciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for CBD Life Sciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CBD Life Sciences LT-Debt-to-Total-Asset Chart

CBD Life Sciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14
LT-Debt-to-Total-Asset
- - - -

CBD Life Sciences Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CBD Life Sciences LT-Debt-to-Total-Asset Calculation

CBD Life Sciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2014 is calculated as

LT Debt to Total Assets (A: Dec. 2014 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2014 )/Total Assets (A: Dec. 2014 )
=0/0.632
=0.00

CBD Life Sciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2015 is calculated as

LT Debt to Total Assets (Q: Sep. 2015 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2015 )/Total Assets (Q: Sep. 2015 )
=0/0.621
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CBD Life Sciences  (OTCPK:CBDL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


CBD Life Sciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of CBD Life Sciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CBD Life Sciences (CBD Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
10853 N. Frank Llyod Wright Boulevard, Suite 108, Scottsdale, AZ, USA, 85259
CBD Life Sciences Inc is developing and marketing a line of cannabidiol based organic products such as hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a full line of pet products. The company is also in the process of developing an anti-aging skin product line.